The start of the 40-subject PK trial of MED2002 (Eroxon®) is in line with expectations. The trial will provide additional safety and tolerability data for Eroxon® and inform the choice of dose range for the subsequent Phase III programme. Meanwhile we look forward to a first out-licensing agreement for Eroxon®, currently expected before the start of Phase III in H1 2018. We continue to view Eroxon® as a differentiated product with significant commercial potential in both prescription and, over t ....
